Optometry Practice for Sale New York: 2026 Seller’s Guide for Owners

Selling an optometry practice for sale new york owners list in 2026 is a different transaction than the same deal in Ohio or Texas, because the New York State Education Department restricts professional corporation ownership to licensed optometrists and because a Manhattan lease can move a valuation by a full EBITDA turn. Optometry practices traded at a median 4.7x EBITDA across the United States in 2025 per CoreValue / DealStats data, but New York City platform deals routinely close at 6x to 8x for groups above $1M EBITDA while upstate solo practices settle between 1.0x and 1.5x SDE. This guide walks through how New York optometry deals actually get priced, structured, and closed.

What This Actually Means for New York Optometry Owners

An optometry practice in New York is two businesses stapled together. The clinical side bills eye exams, contact lens fittings, medical optometry visits, and diagnostic procedures through Medicare, Medicaid, VSP, EyeMed, Davis Vision, and commercial carriers. The optical side sells frames, lenses, contacts, and sunglasses through retail mark-up and managed-vision-care reimbursement. Buyers value the two halves differently, and the mix between them is one of the strongest predictors of the final multiple.

New York Education Law sections 7101 through 7110 govern optometry practice in the state, and the New York State Education Department (NYSED) Office of the Professions enforces the rules. The single most important rule for sellers is the corporate practice doctrine: a professional service corporation (PC or PLLC) that practices optometry in New York can only be owned by licensed optometrists. A private equity fund, a Goldman Sachs portfolio company, or a strategic retailer cannot directly own the PC. That sounds like a deal-killer for non-OD buyers, but the industry solved it years ago through the management services organization (MSO) structure.

The MSO model splits the practice into two legal entities. The PC keeps the license, the clinical staff, the patient charts, and the billing relationships with payors. The MSO buys the non-clinical assets: real estate or lease, equipment, optical inventory, brand, IT, supplier contracts, and back-office staff. The MSO then signs a long-term management services agreement (MSA) with the PC, paying the PC for clinical services and collecting a management fee that captures the economic value of the practice. A friendly OD (sometimes the selling doctor, sometimes a new buyer-side OD) holds the PC equity. Every PE-backed optometry deal in New York closes this way, and a seller who does not understand the structure will sign a worse deal.

The Six Things You Need to Understand Before Listing

1. Practice Size Drives the Buyer Pool and the Multiple

Current state: Most New York optometry practices that come to market are solo-OD shops doing $700K to $1.5M in collected revenue, producing $200K to $500K of seller’s discretionary earnings (SDE). At that size the buyer pool is overwhelmingly individual ODs buying their first practice or small regional groups consolidating one zip code at a time. Multiples sit at 1.0x to 1.5x SDE, with the high end reserved for practices that have a second OD already in place, a long lease, and an EHR that the buyer can actually use.

Target state: A group practice doing $2M to $5M in revenue, with $500K to $2M of EBITDA after a fair-market OD compensation add-back, attracts a different buyer pool. Regional DSOs like Acuity Eyecare Group, IntegraEyes, and Spectrum Vision Partners shop in this range, paying 4x to 6x EBITDA per published industry survey data from VMAIL Vision Monday’s 2025 DSO report. Above $2M EBITDA the buyer pool opens up to the national PE platforms (MyEyeDr, Eye Health America, Quigley Eye Specialists), where multiples climb to 5x to 8x EBITDA depending on growth rate and payor mix.

Impact on outcome: A solo OD doing $400K SDE who sells alone gets roughly $500K. The same OD who brings in a partner, grows to $1.2M EBITDA across two locations over three years, and then sells to a platform at 6x clears $7.2M. The exit math rewards owners who scale before they sell.

2. NYC vs Upstate Geography Changes Everything

Current state: A practice in Manhattan, Brooklyn, Queens, Westchester, or Nassau competes for buyer attention against the rest of the country’s top metros. Platform buyers want density (the ability to add a second, third, and fourth location within driving distance of an existing hub), and the five boroughs plus the inner suburbs offer that density. Manhattan rents are punishing, but the patient density and commercial-insurance mix more than offset.

Target state: Upstate practices in Buffalo, Rochester, Syracuse, Albany, Binghamton, and the smaller cities trade differently. The buyer pool is thinner, the per-exam reimbursement is lower, and the optical retail competition from Walmart Vision, Costco, and warehouse chains is heavier. Multiples for upstate solo practices typically land at 1.0x SDE to 4x EBITDA depending on size, with 4x to 5x being the practical ceiling unless a regional consolidator is actively rolling up that specific metro.

Impact on outcome: The same $1M EBITDA practice can be worth $4M in Rochester and $6.5M in Brooklyn. Sellers in upstate markets should plan a longer marketing process (90 to 150 days) and should be open to seller financing or earn-outs to bridge the valuation gap with buyers who have fewer comparable comps to anchor against.

3. The MSO / PC Structure Is Not Optional

Current state: Many selling ODs walk into the first PE meeting expecting a simple stock sale of their PC, the same deal they would do in Florida or Arizona. NYSED rules prevent that. The buyer must structure as MSO + PC, and the seller is asked to either keep token PC ownership for a transition period or transfer the PC to a buyer-designated friendly OD.

Target state: Get ahead of the structure by talking to a healthcare transactional attorney who has closed New York MSO deals before. Confirm in writing how the management fee is calculated, what the MSA term is (typically 30 to 40 years, with renewal options), and what happens if the PC’s friendly OD becomes unavailable. Confirm that the management fee does not violate New York’s fee-splitting prohibition under Education Law section 6530(19), which has been a focus of NYSED enforcement actions against several DSO models nationally.

Impact on outcome: A clean MSO/PC structure with a defensible management fee closes in 60 to 90 days from LOI. A sloppy structure adds 30 to 60 days of legal back-and-forth, costs an extra $40K to $80K in attorney fees, and sometimes blows the deal entirely when NYSED counsel raises red flags during diligence.

4. Payor Mix Determines Multiple Within the Band

Current state: A New York optometry practice typically runs Medicare at 35% to 45% of collections, Medicaid at 15% to 25% (much higher in NYC outer-borough practices), commercial vision and medical at 30% to 40%, and private pay (mostly optical retail) at 5% to 15%. Buyers price each bucket differently.

Target state: Practices weighted toward commercial vision (VSP, EyeMed, Davis Vision) and private-pay optical command higher multiples because the reimbursement is more predictable and the patient relationship is stickier. Heavy Medicaid mix in NYC (especially Medicaid managed care through Healthfirst, Fidelis, MetroPlus) discounts the multiple by 0.5x to 1.0x EBITDA because reimbursement is lower and audit risk is higher.

Impact on outcome: Two identical $1M EBITDA practices, one 60% commercial and one 40% Medicaid, will get bids 15% to 25% apart from the same buyer pool. Document your payor mix by visit and by collection dollars, separately, before going to market.

5. The Lease Is the Hidden Deal-Breaker

Current state: Most NYC retail leases run 10 years with two 5-year options. By the time an OD decides to sell, the original lease often has 2 to 4 years remaining, with options that the landlord has discretion to refuse to honor on assignment. Platform buyers want at least 5 years of secure tenure (10 is better) so they can fully depreciate equipment and brand investment.

Target state: Before going to market, negotiate either a lease extension or a written landlord consent to assignment with extension. NYC landlords charge for this, often demanding a small rent bump (3% to 5%) and an upfront fee, but a 10-year secure lease can add $200K to $500K to the sale price on a $1M to $2M EBITDA practice.

Impact on outcome: A practice with 18 months remaining on a Manhattan lease will see bids come in at the low end of the range with significant escrow holdbacks tied to lease renewal. A practice with 10 years secure gets the top of the range with no holdback.

6. Staff and Second-OD Coverage Is the Quiet Multiplier

Current state: A solo-OD practice where the selling doctor sees 90% of patients is a single point of failure. New York opticians earn $50K to $75K per year, and a competent second OD in NYC commands $140K to $200K plus benefits. Many owners avoid the cost and stay solo, which caps the practice value.

Target state: Bring in a second OD 12 to 24 months before the planned sale. The second OD takes 30% to 50% of the patient load, the selling OD documents the transition, and the buyer sees a practice that survives the seller’s departure. Buyer-paid retention bonuses for key staff and a non-compete with the second OD are typical at closing.

Impact on outcome: Practices with documented second-OD coverage routinely add 0.5x to 1.5x to the EBITDA multiple at sale. On a $1M EBITDA practice, that is $500K to $1.5M of additional sale price for the cost of one extra OD salary for 18 months.

Worked Example: A Long Island Optometry Practice Exit

Consider a fictional but realistic scenario. Dr. Patel owns a single-location optometry practice in Nassau County, opened in 2008, doing $1.8M in collected revenue in 2025. The practice has 4,200 active patients, runs 35% commercial vision, 38% Medicare, 18% Medicaid managed care, and 9% private optical. SDE for 2025 is $620K after a $200K fair-market replacement OD salary. After adding back personal car lease, family phone plans, and one-time IT migration costs, normalized EBITDA is $540K.

Dr. Patel has two paths.

Path A, sell today as a solo practice. The buyer pool is one or two individual ODs and one regional group. Best bid: 4.2x EBITDA, or roughly $2.27M, with 80% cash at close and 20% seller note over three years at 7%. After legal fees, broker fees if traditional brokered, and tax (long-term capital gains at federal 20% plus NIIT 3.8% plus New York State 10.9%), Dr. Patel nets roughly $1.45M after-tax over four years.

Path B, partner-up and platform exit in 24 months. Dr. Patel brings in Dr. Lee as a 20% partner at start of 2026, paying Dr. Lee $180K plus 20% of incremental profit. Together they open a second location in Suffolk County in late 2026, financed by SBA 7(a). By end of 2027, combined practice does $3.6M revenue, $1.05M EBITDA. Dr. Patel sells the 80% stake to a PE-backed DSO at 6.2x EBITDA on $1.05M = $6.51M enterprise value, with Dr. Patel’s 80% share of equity = $5.21M. The deal is structured 70% cash at close ($3.65M), 20% rollover equity in the platform ($1.04M), and 10% earn-out over two years ($520K). Dr. Lee keeps her 20% and signs a 5-year employment agreement with the platform.

Path B requires patience, capital, and partner risk. It also produces roughly 2.5x the after-tax cash. Most New York optometry exits in 2025 and 2026 are some version of this calculus.

Common Mistakes New York Optometry Sellers Make

Trying to Sell the PC Stock Directly to a DSO

A DSO cannot buy the PC. Period. Sellers who insist on a simple stock deal either get rejected by every institutional buyer or end up with a one-bidder process from a single OD who lacks the capital to pay a top-of-market multiple. The MSO/PC structure is non-negotiable for any buyer above the individual-OD tier.

Ignoring Medicare and Medicaid Audit Exposure

Buyers run full payor audits during diligence. A practice with sloppy modifier coding on 92002, 92012, 92250, or 92133 (the core optometry exam and imaging codes) faces a clawback risk that the buyer will either deduct from the purchase price or wall off in a long indemnification escrow. Clean up the chart documentation 12 months before listing. The Office of Medicaid Inspector General (OMIG) is particularly active in NYC.

Treating Optical Inventory as an Asset Without Counting It

Optical inventory in a busy practice runs $80K to $250K at cost. Buyers will only credit slow-moving stock at deep discount or not at all. Run a real physical count, mark down obsolete frames and sunglasses, and present a cleaned-up inventory number. Trying to pass off three-year-old Coach frames at full wholesale just irritates the buyer’s diligence team.

Overlooking Stark Law and Anti-Kickback Compliance for Optical Referrals

An optometry practice that sells optical from the same location creates a federal Stark and AKS analysis around in-office ancillary services. The exception exists, but the practice must meet the specific safe-harbor conditions. Buyers’ counsel will check. A sloppy referral arrangement (especially if the practice shares profits with a referring ophthalmologist) can scuttle a deal at the eleventh hour.

Underestimating the EHR Migration Cost

Most New York optometry practices run Compulink, RevolutionEHR, OfficeMate / ExamWriter, Crystal PM, or Eyefinity. Platform buyers typically standardize on one EHR across the portfolio. The migration is real work, often $25K to $75K plus 60 to 120 days of staff disruption. Buyers either deduct that cost from purchase price or require the seller to fund it pre-close. Document your EHR setup, data export capability, and integration history clearly.

Skipping the Personal Goodwill vs Enterprise Goodwill Analysis

In a solo OD practice with high SDE, a meaningful portion of value attaches to the selling doctor personally, not the entity. A proper allocation between personal and enterprise goodwill can save 6 to 10 percentage points of federal tax under the Martin Ice Cream and Bross Trucking lines of cases. This requires a defensible valuation and proper deal structure. Sellers who skip this often overpay tax by $100K to $300K on a $2M deal.

Timeline and Process: How a New York Optometry Sale Actually Runs

A well-prepared New York optometry sale runs 6 to 9 months from first valuation conversation to closing wire. The phases below assume the seller engages a buyer-paid M&A advisor or a healthcare-focused intermediary, not a generic business broker.

Phase 1: Pre-Market Preparation (60 to 90 Days)

Gather three years of tax returns, three years of P&L by month, a current chart of accounts mapped to industry benchmarks, the lease, all payor contracts, OD employment agreements, optical inventory count, equipment list with serial numbers, malpractice insurance history, NYSED license status, and Medicare/Medicaid enrollment letters. Engage a healthcare-savvy CPA to normalize EBITDA and identify add-backs. Engage a transactional attorney to review the lease assignment language and PC structure.

Phase 2: Valuation and Buyer List (15 to 30 Days)

The advisor builds a defensible valuation range with comparable transactions from DealStats, CoreValue, and proprietary DSO databases. The advisor builds a tiered buyer list: tier 1 platform DSOs (MyEyeDr, Eye Health America, Quigley, Spectrum Vision Partners, Acuity Eyecare, IntegraEyes), tier 2 regional consolidators, tier 3 strategic retailers (Pearle Vision, Visionworks, Stanton Optical, EssilorLuxottica), and tier 4 individual OD buyers with SBA pre-qualification. A confidential information memorandum (CIM) is drafted.

Phase 3: Market Outreach and Initial Bids (30 to 60 Days)

The advisor signs NDAs with qualified buyers and distributes the CIM. Management presentations are scheduled for the top 4 to 6 interested buyers. Indications of interest (IOIs) come back with valuation ranges, deal structure preferences, and diligence requirements. The seller picks 2 to 3 finalists for management meetings and site visits.

Phase 4: LOI and Diligence (45 to 75 Days)

The winning bidder signs a letter of intent with exclusivity (typically 60 to 90 days). Diligence covers financial (Quality of Earnings by buyer’s accountant), legal (corporate, payor, licensing, lease, employment), clinical (chart review, compliance audit), and operational (equipment condition, EHR data quality, staff interviews). The MSO/PC structure is finalized with both sides’ counsel.

Phase 5: Definitive Documents and Closing (30 to 45 Days)

The asset purchase agreement (APA) or membership interest purchase agreement (MIPA) is drafted alongside the management services agreement, the OD employment and equity rollover documents, real estate or lease assignment, and escrow agreements. NYSED notification (if any), lender consents, and landlord consents are obtained. The deal closes by wire on the target date.

Phase 6: Post-Close Transition (90 to 180 Days)

The selling OD typically stays for 6 to 24 months as an employee of the new PC under the MSA. Staff are introduced to the new ownership, EHR migration begins, billing transitions, and the optical inventory is re-stocked under platform contracts. The seller’s earn-out or rollover equity gets measured against agreed milestones.

Frequently Asked Questions

Can a non-optometrist buy an optometry practice in New York?

Not directly. New York Education Law restricts ownership of professional service corporations practicing optometry to licensed New York optometrists. Non-OD buyers, including private equity funds and strategic retailers, structure the transaction as a management services organization that owns the non-clinical assets and contracts with a separate PC owned by a licensed OD through a long-term management services agreement. Every PE-backed New York optometry deal closes this way.

What multiple does a New York optometry practice sell for in 2026?

Solo practices with $250K to $500K SDE typically trade at 1.0x to 1.5x SDE, mostly to individual OD buyers. Group practices with $500K to $2M EBITDA trade at 4x to 6x EBITDA to regional DSOs. Practices above $2M EBITDA trade at 5x to 8x EBITDA to national PE-backed platforms, with NYC and inner-suburb practices commanding the top of the range and upstate practices typically 1x to 2x EBITDA lower per VMAIL Vision Monday and DealStats 2025 data.

How long does it take to sell an optometry practice in New York?

A well-prepared practice closes 6 to 9 months from first advisor engagement to wire. Pre-market preparation runs 60 to 90 days, market outreach and bid collection 30 to 60 days, LOI and diligence 45 to 75 days, and definitive documents and closing 30 to 45 days. Practices with messy financials, expiring leases, or unclear corporate structure can stretch to 12 to 18 months.

What do I do about the lease before I sell?

Negotiate at least 5 years of secure tenure before going to market, ideally 10. Most NYC commercial leases require landlord consent to assignment, which the landlord can use to extract a rent bump or fee. A 5-year extension negotiated 12 months before listing can add $200K to $500K to the sale price on a $1M to $2M EBITDA practice. Skipping this step typically forces the buyer to either discount the bid or hold back significant escrow tied to renewal.

Do I pay the M&A advisor or does the buyer?

At CT Acquisitions, the buyer pays the advisor fee out of the transaction proceeds at closing. The seller does not write a check to the advisor. This is standard practice in healthcare M&A, where institutional buyers expect to pay the buy-side coverage fee, and it removes the seller’s incentive concern about whether the advisor is pushing for a quick close versus the best price.

What happens to my staff after the sale?

Most platform buyers retain front-desk, optical, and technical staff because operational continuity protects the patient relationships. Retention bonuses of 5% to 15% of annual salary, payable at 6 and 12 months post-close, are typical for key staff. The selling OD usually signs a 1 to 3 year employment agreement with the new PC, and the second OD (if one exists) is typically retained on a 3 to 5 year contract with non-compete.

How CT Acquisitions Approaches New York Optometry Sales

CT Acquisitions runs a buyer-paid M&A process for healthcare practice sellers. We do not list practices on BizBuySell or run a brokered marketplace. We work directly with the platform DSOs, PE-backed consolidators, and strategic retailers actively buying in New York, we know their deal teams personally, and we know which buyers will pay the top of the range for a Manhattan practice versus an Albany practice versus a Long Island practice.

Because the buyer pays our fee, the seller gets a full institutional process without writing a check to us at any stage. The seller’s only out-of-pocket costs are their own legal and accounting fees, which a buyer-paid process actually reduces because we run a tight diligence and document workflow that does not waste the seller’s counsel hours. For sellers ready to start, the first step is a confidential 30-minute valuation call.

What to Do Next

If you own a New York optometry practice and you are thinking about a sale in the next 12 to 36 months, the smartest move you can make today is a confidential valuation review. Whether the answer is “sell now at top of market” or “spend 18 months on the second-OD and lease prep work first,” you will make a better decision with real numbers than with guesses. There is no cost, no obligation, and no broker listing agreement.